Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum
Cantor Fitzgerald raised its price target for MannKind Corp. (NASDAQ:MNKD) to $10.00, citing momentum for Tyvaso DPI and a delayed competitor. The firm expects profitability in 2026, with revenue growth of 30% and a 75% gross margin. MannKind reported Q3 2026 revenue of $101.9M, missing estimates but showing a smaller loss than expected. The company's commercial products and royalties drove growth.
How this was made
The 30-second read
Why it matters
The upgrade could attract new buying interest, but execution risk remains.
Market read
Analyst upgrade provides a fresh catalyst for MNKD, offering a potential short‑term trade idea.
What to watch
Potential delays in pipeline studies or competitive pressures could temper upside.
Background
The article reports an analyst price‑target revision for MannKind Corp., a small‑cap biotech, and recaps its recent Q3 results.
Ticker impact
Cantor Fitzgerald raised its price target for MannKind Corp. (MNKD) to $10 from $8, citing stronger Tyvaso momentum and upcoming product launches.
likely upward pressure as investors price in the new target and growth expectations
The target increase of 115% implies significant upside; the analyst highlighted revenue growth and pipeline progress.
Market effects
Positive outlook may lift other biotech stocks focused on inhaled therapies.
U.S. biotech sector could see modest gains.
Limited to investors tracking small-cap biotech equities.
Counterpoint
The target raise may be premature given MNKD's recent revenue miss and lack of profitability.
Key entities
- AnalystCantor Fitzgerald
Raised MNKD price target to $10.
- CompanyMannKind Corp.
Biotech firm developing Tyvaso DPI and other inhaled therapies.
